Published articles

Search collections:

Sort by:	Display results:	Output format:

Published articles	1 records found	Search took 0.02 seconds.

18 p, 8.9 MB

Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma / Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ; Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ; Giuntini, Fabio (Vall d'Hebron Institut d'Oncologia) ; González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ; Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ; Casacuberta-Serra, Sílvia (Vall d'Hebron Institut d'Oncologia) ; Jauset, Toni (Vall d'Hebron Institut d'Oncologia) ; Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ; Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ; Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ; Foradada Felip, Laia (Vall d'Hebron Institut d'Oncologia) ; Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ; Nonell, Lara (Vall d'Hebron Institut d'Oncologia) ; Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ; Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ; Soucek, Laura (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. [...]
2023 - DOI (Digital Object Identifier)

10.1101/gad.350078.122
Genes & Development, Vol. 37 (april 2023) , p. 303-320

Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.